Autoimmune Diseases  >>  glatiramer acetate  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
glatiramer acetate / Generic mfg.
NCT00238654: A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

Completed
N/A
257
US
Teva Neuroscience, Inc.
Multiple Sclerosis
07/08
07/08
NCT00203086: A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis

Completed
N/A
30
US, Canada
Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis
10/09
12/09
NCT00819195: Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Checkmark Data
Oct 2010 - Oct 2010: Data
Completed
N/A
17
US
Glatiramer acetate, Copaxone
University of California, San Francisco, National Multiple Sclerosis Society, Teva Neuroscience, Inc.
Multiple Sclerosis
09/12
09/12
TOP MS, NCT00819000: Therapy Optimization in Multiple Sclerosis (MS)

Checkmark
Mar 2014 - Mar 2014: 
Checkmark AAN 2014: Multiple sclerosis
Feb 2014 - Feb 2014: AAN 2014: Multiple sclerosis
Checkmark ECTRIMS 2013: Multiple sclerosis (TOP MS)
More
Completed
N/A
2878
US
Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b, Copaxone®, Avonex®, Rebif®, Betaseron®
Teva Neuroscience, Inc.
Multiple Sclerosis
12/12
01/13
NCT01456416: Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

Completed
N/A
10
US
University of Southern California, Teva Pharmaceuticals USA
Relapsing Remitting Multiple Sclerosis
04/13
04/13
GAO, NCT02017808: Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months

Completed
N/A
100
US
University at Buffalo, Teva Pharmaceuticals USA
Multiple Sclerosis
12/14
12/14
NCT01903291: Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

Checkmark CMSC 2016: RESPOND
Jun 2016 - Jun 2016: CMSC 2016: RESPOND
Completed
N/A
333
US
dimethyl fumarate, Tecfidera, BG00012, DMF
Biogen
Relapsing Forms of Multiple Sclerosis
02/16
02/16
IMPROVE, NCT02323269: Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

Terminated
N/A
24
Canada
dimethyl fumarate, DMF, BG00012, Tecfidera
Biogen
Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis
03/16
03/16
EFFECT, NCT02776072: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)

Completed
N/A
2978
US, Canada, Europe, RoW
Biogen
Multiple Sclerosis
12/16
12/16

Download Options